Betrixaban represents the first oral and long-lasting treatment to prevent deep vein thrombosis and pulmonary embolisms in acutely ill nonsurgical patients. The once-daily pill may be used in both hospital and home settings.
In the hospital setting, the drug will compete with the widely-used blood thinner, heparin, and Sanofi’s Lovenox. Analysts project Betrixaban will generate $313 million in sales by 2020, according to Thomson Reuters data.
More articles on supply chain:
Viewpoint: 4 insights into postapproval monitoring of medical devices
6 drugmakers in the headlines
Philips acquires noninvasive neurodiagnostics company for $36M
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
